2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Sattva S. Neelapu, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, Andre Goy, Peter A. McSweeney, Javier Munoz, Tanya Siddiqi, Julio C. Chavez, Alex F. Herrera, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jenny J. Kim, William Y. Go, Frederick L. Locke
Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Dana-Farber Cancer Institute, Stanford Medicine, Stanford University, University of Miami Health System, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Mayo Clinic, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Cleveland Clinic, University of California, Los Angeles, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Rochester Medicine, University of Rochester, Loyola University Medical Center, Sarah Cannon, University of Iowa, Hackensack University Medical Center, Colorado Blood Cancer Institute, Banner MD Anderson Cancer Center, City Of Hope National Medical Center, Moffitt Cancer Center, Kite (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2904883443